Superior Planning, LLC’s Cytokinetics CYTK Stock Holding History

Superior Planning, LLC’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$17.3K	Buy	+262	New	+$20K	0.01%	745

Other funds holding CYTK

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Superior Planning, LLC's CYTK Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Cytokinetics (CYTK) in Q3 2026: 262 shares worth $17.3K. The stake represents 0.01% of the portfolio and ranks #745 among its holdings.

282 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

Superior Planning, LLC held 262 shares of Cytokinetics worth $17.3K as of Q3 2026.
Cytokinetics was a new Superior Planning, LLC position in Q3 2026.
Cytokinetics made up 0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #745 holding.
282 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.